Clivarin and other LMWHs in an ex vivo cardiopulmonary bypass model. Studies on contact activation.
A large number of low-molecular-weight heparin (LMWH) preparations are contending for superiority and their pharmacological properties need to be assessed. Thus experimental and clinical experience accumulated from one LMWH can only be extrapolated to a limited extent to another LMWH.
Heller
W
W
Department of Cardiovascular Surgery, University of Tubingen, Germany.
Wendel
H P
HP
D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000032:analysis; D002315:Cardiopulmonary Bypass / Q000295:instrumentation; D003167:Complement Activation / Q000187:drug effects*; D003174:Complement C1 Inactivator Proteins / Q000502:physiology; D017984:Enoxaparin / Q000494:pharmacology*; D005174:Factor XII / Q000502:physiology; D005342:Fibrinolysis / Q000187:drug effects*; D005344:Fibrinopeptide A / Q000032:analysis; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology*; D006801:Humans; D016234:Kallikrein-Kinin System / Q000187:drug effects*; D019272:Leukocyte Elastase; D017762:Nadroparin / Q000494:pharmacology*; D010196:Pancreatic Elastase / Q000032:analysis; D010865:Pilot Projects; D010976:Platelet Count / Q000187:drug effects
D001779:Blood Coagulation Factors; D003174:Complement C1 Inactivator Proteins; D017984:Enoxaparin; D006495:Heparin, Low-Molecular-Weight; D017762:Nadroparin; D005344:Fibrinopeptide A; C094240:reviparin; D005174:Factor XII; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase